Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9–14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial
Author:
Tsiri Agbenyega,Anne E Schuind,Samuel Adjei,Kalpana Antony,John J Aponte,Patrick B Y Buabeng,John D Clemens,Lokman Hossain,Troy J Kemp,Laina D Mercer,Ligia A Pinto,Firdausi Qadri,Kristen Sukraw,Niranjan Bhat,Khalequ Zaman
Publication:
The Lancet Infectious Diseases
© 2025 The Author(s). Published by Elsevier Ltd.